CME Breakfast Symposium
Friday, August 7, 2020 · 6:00 – 7:15 AM
Challenging the Status-Quo: The Cardiorenal Protection with SGLT-2 Inhibitors in T2DM and Beyond--Expert Debate and Discussions
Chaired by: TBD
After completing this activity, the participant should be better able to:
Review the association and the pathophysiology between T2D and CKD, and the impact of concomitant CKD and T2D on patient outcomes
Employ the diagnostic criteria according to evidence-based guidelines for DKD in patients with T2DM at risk for kidney disease progression
Utilize current treatment options for patients with DKD based on identified benefits and risks, and current guideline recommendations
Review the efficacy and safety of emerging DKD treatments based on the latest evidence
This activity is jointly provided by Postgraduate Institute for Medicine and CMHC. Supported by an educational grant from AstraZeneca.
This activity is approved for AMA PRA Category 1 Credits™. This activity is eligible for ABIM MOC, ACPE, ANCC and CDR credit, see final activity announcement for specific details. For overall accreditation information on CMHC West 2020, please click here.